Subtopic Deep Dive
Neurodevelopmental Outcomes After Retinopathy of Prematurity
Research Guide
What is Neurodevelopmental Outcomes After Retinopathy of Prematurity?
Neurodevelopmental Outcomes After Retinopathy of Prematurity examines long-term cognitive, motor, and visual development in preterm infants treated for ROP, distinguishing treatment effects from prematurity risks using cohort studies and neuroimaging.
Longitudinal studies track Bayley Scales scores and neurosensory impairment in ROP survivors up to 18-24 months. Key morbidities like severe ROP, bronchopulmonary dysplasia, and brain injury predict poor outcomes (Schmidt et al., 2003, 621 citations). Bevacizumab treatment shows no significant neurodevelopmental differences versus laser at 2 years (Morin et al., 2016, 283 citations; Lien et al., 2016, 135 citations).
Why It Matters
Findings guide parental counseling on risks for extremely low-birth-weight infants, where severe ROP triples neurosensory impairment odds (Schmidt et al., 2003). They inform early intervention timing, as visual impairment correlates with motor delays in periventricular leucomalacia cases (Cioni et al., 2000). With rising preterm survival, these outcomes shape anti-VEGF safety monitoring, noting potential systemic effects (Sankar et al., 2018; Morin et al., 2016).
Key Research Challenges
Confounding Prematurity Risks
Distinguishing ROP treatment effects from baseline preterm morbidities like brain injury challenges attribution (Schmidt et al., 2003). Studies must adjust for oxygen saturation and hypoglycaemia (Askie et al., 2018; Paudel et al., 2017).
Long-term Bevacizumab Safety
Systemic VEGF inhibition may delay neurodevelopment, but 2-year follow-ups show no differences versus laser (Morin et al., 2016; Lien et al., 2016). Cochrane review calls for childhood outcomes (Sankar et al., 2018).
Neuroimaging-Outcome Correlation
Linking MRI findings in periventricular leucomalacia to visual and cognitive scores requires standardized assessments at 1-3 years (Cioni et al., 2000). Hypoxia-ischaemia models complicate causality (Millar et al., 2017).
Essential Papers
Impact of Bronchopulmonary Dysplasia, Brain Injury, and Severe Retinopathy on the Outcome of Extremely Low-Birth-Weight Infants at 18 Months
Barbara Schmidt, Elizabeth Asztalos, Robin S. Roberts et al. · 2003 · JAMA · 621 citations
In ELBW infants who survive to a postmenstrual age of 36 weeks, a simple count of 3 common neonatal morbidities strongly predicts the risk of later death or neurosensory impairment.
Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration
Lisa Askie, Brian A. Darlow, Neil Finer et al. · 2018 · JAMA · 405 citations
In this prospectively planned meta-analysis of individual participant data from extremely preterm infants, there was no significant difference between a lower Spo2 target range compared with a high...
Neonatal Hypoxia Ischaemia: Mechanisms, Models, and Therapeutic Challenges
Lancelot Jamie Millar, Lei Shi, Anna Hoerder‐Suabedissen et al. · 2017 · Frontiers in Cellular Neuroscience · 339 citations
Neonatal hypoxia-ischaemia (HI) is the most common cause of death and disability in human neonates, and is often associated with persistent motor, sensory, and cognitive impairment. Improved intens...
Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity
Julie Morin, Thuy Mai Luu, Rosanne Superstein et al. · 2016 · PEDIATRICS · 283 citations
BACKGROUND AND OBJECTIVE: Bevacizumab intravitreal injection, a vascular endothelial growth factor inhibitor, is used to treat retinopathy of prematurity (ROP). However, concerns have been raised r...
Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity
Mari Jeeva Sankar, Jhuma Sankar, Parijat Chandra · 2018 · Cochrane Database of Systematic Reviews · 221 citations
Further studies are needed to evaluate the effect of anti-VEGF agents on structural and functional outcomes in childhood and delayed systemic effects including adverse neurodevelopmental outcomes.
Neonatal Hypoglycaemia and Visual Development: A Review
Nabin Paudel, Arijit Chakraborty, Nicola Anstice et al. · 2017 · Neonatology · 209 citations
<b><i>Background:</i></b> Many newborn babies experience low blood glucose concentrations, a condition referred to as neonatal hypoglycaemia (NH). The effect of NH on visual...
Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies
José Carlos Rivera, Mari Holm, Dordi Austeng et al. · 2017 · Journal of Neuroinflammation · 146 citations
Reading Guide
Foundational Papers
Start with Schmidt et al. (2003, 621 citations) for morbidity predictors in ELBW infants, then Cioni et al. (2000, 110 citations) for MRI-visual correlations, Dale & Sonksen (2002, 102 citations) for visual impairment setbacks.
Recent Advances
Morin et al. (2016, 283 citations) and Lien et al. (2016, 135 citations) on bevacizumab safety; Sankar et al. (2018, 221 citations) Cochrane on anti-VEGF gaps.
Core Methods
Bayley Scales for cognition/motor; MRI for brain structure; cohort comparisons of laser vs intravitreal bevacizumab; adjustment for BPD, hypoxia (Schmidt 2003; Askie 2018).
How PapersFlow Helps You Research Neurodevelopmental Outcomes After Retinopathy of Prematurity
Discover & Search
Research Agent uses citationGraph on Schmidt et al. (2003) to map 621-citation network linking ROP to neurosensory impairment, then findSimilarPapers for bevacizumab cohorts like Morin et al. (2016). exaSearch queries 'ROP neurodevelopment Bayley scores' to uncover 250M+ OpenAlex papers on preterm outcomes.
Analyze & Verify
Analysis Agent applies readPaperContent to extract Bayley III scores from Morin et al. (2016), then runPythonAnalysis for meta-analysis of impairment rates across Schmidt (2003) and Lien (2016). verifyResponse with CoVe flags contradictions in oxygen targeting effects (Askie et al., 2018); GRADE grades evidence as moderate for bevacizumab safety.
Synthesize & Write
Synthesis Agent detects gaps in long-term (>2-year) bevacizumab data (Sankar et al., 2018), flags contradictions between laser and anti-VEGF motor outcomes. Writing Agent uses latexEditText for cohort tables, latexSyncCitations for 10-paper bibliography, latexCompile for review manuscript; exportMermaid diagrams MRI-visual correlations from Cioni (2000).
Use Cases
"Run statistics on Bayley scores in ROP bevacizumab vs laser trials"
Research Agent → searchPapers 'ROP bevacizumab neurodevelopment' → Analysis Agent → readPaperContent (Morin 2016, Lien 2016) → runPythonAnalysis (pandas meta-analysis of cognitive scores, t-test p-values) → researcher gets CSV of effect sizes and forest plot.
"Draft LaTeX review on ROP neurodevelopmental risks with citations"
Research Agent → citationGraph (Schmidt 2003) → Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (10 papers) → latexCompile → researcher gets PDF manuscript with figures.
"Find code for preterm kinematic analysis in ROP studies"
Research Agent → paperExtractUrls (Fallang 2003) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts for movement quality metrics linked to visual outcomes.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (50+ ROP outcome papers) → citationGraph → DeepScan (7-step GRADE assessment of Schmidt 2003, Morin 2016) → structured report on impairment predictors. Theorizer generates hypotheses on VEGF-brain links from Sankar (2018) + Millar (2017). Chain-of-Verification/CoVe verifies all claims across cohorts.
Frequently Asked Questions
What defines neurodevelopmental outcomes after ROP?
Outcomes include Bayley Scales for cognitive/motor scores, neurosensory impairment, and visual function up to 18-24 months in preterm survivors (Schmidt et al., 2003; Morin et al., 2016).
What methods assess these outcomes?
Longitudinal cohorts use Bayley III, MRI for periventricular leucomalacia, and compare laser vs bevacizumab (Cioni et al., 2000; Lien et al., 2016).
What are key papers?
Schmidt et al. (2003, 621 citations) links ROP to impairment; Morin et al. (2016, 283 citations) clears bevacizumab at 2 years.
What open problems remain?
Long-term (>2 years) anti-VEGF effects and confounding by hypoxia need study (Sankar et al., 2018; Millar et al., 2017).
Research Retinopathy of Prematurity Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neurodevelopmental Outcomes After Retinopathy of Prematurity with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers